Emerging treatments such as anti-GD2 therapies are improving outcomes for children with relapsed/refractory, high-risk neuroblastoma. The changing therapeutic landscape has left knowledge gaps, with clinicians needing assistance with understanding how to integrate new agents, administer new treatments, and manage associated side effects.

To address these issues, PlatformQ Health teamed up with Advances in Neuroblastoma Research Association and Solving Kids’ Cancer to develop two one-hour CME programs for clinicians, patients, and caregivers.

On October 21-25th, PlatformQ Health will present the program outcomes at the 53rd Congress of the International Society of Paediatric Oncology Virtual Congress, which brings together thousands of global members including doctors, nurses, researchers, scientists and other healthcare professionals to advance diagnosis, treatment and care for children and adolescents with cancer. 

The outcomes presented show that 1,299 healthcare providers and 946 families/caregivers participated in the live sessions, resulting in more than 703 CE credits awarded. The program was highly engaging, with 162 polling responses, 213 slide downloads, and 19,979 video views.

The initiative was successful in improving clinical and behavioral impact across the care team related to newer therapies, their administration/management, treatment adherence, and family communication. 62% of learners reported that the activity positively impacted their clinical practice. Participants highlighted their ability to differentiate between new therapies, and educate patients on side effect management.






















Have questions about the posters or want to learn more about how PlatformQ Health is delivering impactful education to HCPs and patients? Email us at digital@platformq.com.